Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation

Rotow Julia K.; Woodard Gavitt A.; Urisman Anatoly; McCoach Caroline E.; Bivona Trever G.; Elicker Brett M.; Jablons David M.; Blakely Collin M.

首页> 外文期刊>Clinical lung cancer >Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation

【24h】

Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation

机译：在肺腺癌患者中对Neoadjuvant Croizotinib的病理完全反应，具有遇到外显子14跳过突变

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical lung cancer》 |2019年第2期|共5页
作者
Rotow Julia K.; Woodard Gavitt A.; Urisman Anatoly; McCoach Caroline E.; Bivona Trever G.; Elicker Brett M.; Jablons David M.; Blakely Collin M.;
展开▼
作者单位

Univ Calif San Francisco Dept Med San Francisco CA USA;

Univ Calif San Francisco Dept Surg San Francisco CA USA;

Univ Calif San Francisco Dept Pathol San Francisco CA 94140 USA;

Univ Calif San Francisco Dept Med San Francisco CA USA;

Univ Calif San Francisco Dept Med San Francisco CA USA;

Univ Calif San Francisco Dept Radiol San Francisco CA USA;

Univ Calif San Francisco Dept Surg San Francisco CA USA;

Univ Calif San Francisco Dept Med San Francisco CA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Non-small cell lung cancer; Perioperative; Stage III; Targeted therapy; Tyrosine kinase inhibitor;

机译：非小细胞肺癌;围手术期;III阶段;靶向治疗;酪氨酸激酶抑制剂;

相似文献

外文文献
中文文献
专利

1. Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation [J] . Rotow Julia K., Woodard Gavitt A., Urisman Anatoly, Clinical lung cancer . 2019,第2期

机译：在肺腺癌患者中对Neoadjuvant Croizotinib的病理完全反应，具有遇到外显子14跳过突变
2. Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation [J] . Jorge Susan E., Schulman Sol, Freed Jason A., Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2015,第3期

机译：MET扩增或MET外显子14跳跃突变对肺腺癌中多靶点MET / ALK / ROS1抑制剂克唑替尼和共现突变的反应
3. Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation [J] . Ruo-Yan Qin, Ling-Shuang Liu, Hui-Yong Zhang, Medicine. . 2021,第4期

机译：患有肺腺癌患者患者患有间充质 - 上皮过渡因子外显子14的患者患者的反应
4. Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Using Deep Learning with Integrative Imaging, Molecular and Demographic Data [C] . Hongyi Duanmu, Pauline Boning Huang, Srinidhi Brahmavar, International Conference on Medical Image Computing and Computer-Assisted Intervention . 2020

机译：利用综合成像，分子和人口统计数据预测对乳腺癌新辅助化疗的病理完全反应
5. Using Preoperative Mri-guided Biopsies to Predict Pathologic Complete Response after Neoadjuvant Chemotherapy in Breast Cancer [D] . Kim, Jiyoon. 2019

机译：在乳腺癌新辅助化疗后使用术前Mri引导的活检来预测病理完全缓解
6. Lazarus-type response to crizotinib in a patient with poor performance status and advanced MET exon 14 skipping mutation-positive lung adenocarcinoma [O] . Meghan Shea, Mark S. Huberman, Daniel B. Costa -1

机译：表现状态差且MET外显子14跳过突变阳性肺腺癌的晚期患者对克唑替尼的Lazarus型反应
7. Correction: Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping [O] . 2016

机译：校正：响应患有阶段肺腺癌患者患者患者的抑制剂，含有符合EXON 14跳过的突变

Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation

著录项

相似文献

相关主题

期刊订阅